Summarized by Masters of Longevity from Longevity Technology.
Nanoscope will present conference updates on emerging optogenetic and retinal-disease research, previewing clinical-data talks and long-term study findings.
Key Takeaways
- Jordi Mones, MD, PhD will present direct‑to‑phase‑2 randomized controlled trial data on sonpiretigene isteparvovec optogenetic therapy.
- Benjamin Bakall, MD, PhD will present four‑year REMAIN extension study data showing lasting vision improvement with MCO‑010.
- Nanoscope states its MOGENRY intravitreal optogenetic therapy has an FDA biologics license application accepted and filed following RESTORE phase 2b/3 results.
